Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel Sells 19,820 Shares

Disc Medicine, Inc. (NASDAQ:IRON) CEO John D. Quisel sold 19,820 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $63.14, for a total value of $1,251,434.80. Following the completion of the transaction, the chief executive officer now owns 72,065 shares in the company, valued at approximately $4,550,184.10. This trade represents a 21.57 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Disc Medicine Stock Up 0.8 %

NASDAQ:IRON opened at $65.54 on Friday. The company has a market capitalization of $1.95 billion, a P/E ratio of -16.47 and a beta of 0.76. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60. The stock’s fifty day moving average is $60.14 and its two-hundred day moving average is $51.28.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Tuesday, November 12th. The company reported ($0.89) earnings per share for the quarter, topping the consensus estimate of ($1.04) by $0.15. Sell-side analysts anticipate that Disc Medicine, Inc. will post -4.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its stake in shares of Disc Medicine by 16.1% in the third quarter. JPMorgan Chase & Co. now owns 16,255 shares of the company’s stock valued at $799,000 after buying an additional 2,257 shares in the last quarter. Exome Asset Management LLC boosted its holdings in Disc Medicine by 5.8% during the 3rd quarter. Exome Asset Management LLC now owns 64,516 shares of the company’s stock valued at $3,170,000 after acquiring an additional 3,516 shares during the period. Teachers Retirement System of The State of Kentucky grew its position in Disc Medicine by 38.7% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 19,560 shares of the company’s stock valued at $961,000 after acquiring an additional 5,458 shares in the last quarter. Geode Capital Management LLC increased its stake in Disc Medicine by 17.6% during the third quarter. Geode Capital Management LLC now owns 474,719 shares of the company’s stock worth $23,333,000 after purchasing an additional 70,983 shares during the period. Finally, Barclays PLC lifted its position in shares of Disc Medicine by 123.7% during the third quarter. Barclays PLC now owns 40,145 shares of the company’s stock worth $1,972,000 after purchasing an additional 22,202 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

IRON has been the topic of a number of research reports. Morgan Stanley upgraded Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective on the stock in a report on Tuesday, November 5th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $85.00 price objective on shares of Disc Medicine in a research note on Tuesday, October 15th. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their target price for the stock from $66.00 to $110.00 in a research note on Monday, November 4th. HC Wainwright restated a “buy” rating and issued a $118.00 price target on shares of Disc Medicine in a research report on Monday, December 9th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $83.00 price target on shares of Disc Medicine in a report on Monday, December 9th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $87.50.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.